COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 9 FDA records to the applicant name Kardium, Inc.. It includes 1 original PMA approval. 3 entries are PMA supplements. 5 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Aug 27, 2025 to Oct 27, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code QZI appears in 9 of the 9 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P240044, with 9 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 8518 Glenlyon Pkwy., Unit 155, Burnaby, V5J OB6. Recorded on P240044/S007, decision dated Oct 27, 2026.
Device categories in this collection
Percutaneous Cardiac Ablation Catheter For Treatment Of Atrial Fibrillation With Irreversible Electroporation.
Changes described in PMA records
FDA lists PMA supplement P240044/S007 for Kardium, Inc.'s Globe® Catheter and Globe® Pulsed Field System as approved on 2026-10-27. The supplement is classified as a Real-Time Process change for design/components/specifications/material. The S007 suffix ties the record to the original P240044 approval rather than constituting a separate approval of the complete system.
The reported purpose is an update to the flexible circuits of the Globe® Catheter array, which uses irreversible electroporation for atrial fibrillation ablation in the cardiovascular category under product code QZI. Beyond this field-level description, the database entry does not disclose the prior circuit design, the nature of the change, test methods, or performance results, and it does not present independent proof of safety or clinical effectiveness; the approval status is the agency's decision on the manufacturing change as described.
FDA approval-order wording
approval for update to the flexible circuits of the Globe Catheter array
Oct 27, 2026 · Real-Time ProcessThe FDA record for P240044/S008 describes a 30-Day Notice submitted by Kardium, Inc. for the Globe Pulsed Field System and Globe Catheter, a percutaneous cardiac ablation catheter for atrial fibrillation using irreversible electroporation. The stated change is a modification to the sterilization cycle parameters and the use of a larger maximum sterilization load.
The listed reason is a process change involving the manufacturer, sterilizer, packager or supplier. This supplement sits under the original PMA identifier P240044; the record does not establish the original approval date, prior sterilization settings, or the specific parameter values changed. The statement reports the applicant's stated purpose, not independent evidence of safety or clinical effectiveness, and the decision date in the record is 2026-10-23.
FDA approval-order wording
modification to the sterilization cycle parameters and use of a larger maximum sterilization load
Oct 23, 2026 · 30-Day NoticeFDA’s recorded scope: manufacturing change to eliminate a redundant dielectric strength test
Aug 20, 2026 · 30-Day NoticeFDA’s recorded scope: approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240044
Jun 23, 2026 · Normal 180 Day Track No User FeeFDA’s recorded scope: leak test process and equipment change
Jun 12, 2026 · 30-Day NoticeSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.